Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 915-919

  Bashir, Qaiser ^a   Munsell, Mark F ^a   Giralt, Sergio ^b   De Padua Silva, Leandro ^a   Sharma, Manish ^c   Couriel, Daniel ^d   Chiattone, Alexandre ^a   Popat, Uday ^a   Qazilbash, Muzaffar H ^a   Fernandez Vina, Marcelo ^a   Champlin, Richard E ^a   De Lima, Marcos J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

ATG; graft versus host disease; hematopoietic cell transplant

Indexed keywords

BORTEZOMIB; FLUDARABINE; MELPHALAN; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; TREATMENT RESPONSE;

ADULT; AGED; ANTILYMPHOCYTE SERUM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 84860009428     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.634039     Document Type: Article

References (21)

1. Frassoni F. Anti-T-cell globulin: an essential ingredient for haematopoietic cell transplantation? Lancet Oncol 2009;10:839.
2. Brayman K. New insights into the mechanisms of action of thymoglobulin. Transplantation 2007;84:S3-S4. (Pubitemid 350294705)
3. Zand MS, Vo T, Pellegrin T, et al. Apoptosis and complementmediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood 2006;107:2895-2903.
4. Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005;79:1507-1515. (Pubitemid 40847581)
5. Lowsky R. Th ymoglobulin and regulatory T cells in organ and hematopoietic cell transplantation. Transplantation 2007;84: S20-S26. (Pubitemid 350294708)
6. Finke J, Bethge WA, Schmoor C, et al. Standard graft-versushost disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009;10:855-864.
7. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001;98:2942-2947.
8. Champlin RE, Perez WS, Passweg JR, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007;109:4582-4585. (Pubitemid 46743430)
9. Remberger M, Svahn BM, Mattsson J, et al. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004;78:122-127.
10. Seidel MG, Fritsch G, Matthes-Martin S, et al. Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2005;27: 532-536. (Pubitemid 41541069)
11. Parmar S, Del Lima M, Zou Y, et al. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 2009;114:2884-2887.
12. Przepiorka D, Khouri I, Ippoliti C, et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant 1999;24:763-768. (Pubitemid 29469277)
13. Berry DA, Eick SG. Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. Stat Med 1995;14:231-246.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
15. Deeg HJ, Storer BE, Boeckh M, et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006;12:573-584. (Pubitemid 43956362)
16. Schattenberg A, van der Meer A, Preijers F, et al. Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors. Bone Marrow Transplant 2004;33:1115-1121. (Pubitemid 38786501)
17. Basara N, Baurmann H, Kolbe K, et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 2005;35:1011-1018. (Pubitemid 40711839)
18. Remberger M, Sundberg B. Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica 2005;90:931-938. (Pubitemid 41020296)
19. Bacigalupo A, Lamparelli T, Milone G, et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+ 7 after alternative donor transplants. Bone Marrow Transplant 2010;45:385-391.
20. Podgorny PJ, Ugarte-Torres A, Liu Y, et al. High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vshost disease and high likelihood of posttransplant lymphoproliferative disorder. Biol Blood Marrow Transplant 2010;16:915-926.
21. Remberger M, Sundberg B. Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. Biol Blood Marrow Transplant 2009;15:996-999.